Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Michigan.
Press releases published on September 3, 2025
Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth
GlobeNewswire
·
September 3, 2025
ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin …
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
GlobeNewswire
·
September 3, 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, …
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
GlobeNewswire
·
September 3, 2025
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) setting Ronde-cel is Lyell’s …
WellSpan Health announces new collaboration with General Catalyst’s Health Assurance Transformation Company
GlobeNewswire
·
September 3, 2025
York, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- WellSpan Health today announced a new collaboration with General Catalyst's Health Assurance Transformation Company (HATCo), representing an expansion of a strategic partnership started in 2023. Under the new …
STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules
GlobeNewswire
·
September 3, 2025
HORSHAM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025
GlobeNewswire
·
September 3, 2025
Company cancels the Equity Line of Credit (ELOC) UNIONDALE, NY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that …
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
GlobeNewswire
·
September 3, 2025
Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan. Company also announces notification by Nasdaq …
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
GlobeNewswire
·
September 3, 2025
ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from kidney cells, and it upregulates cholesterol …
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
GlobeNewswire
·
September 3, 2025
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study has …
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
GlobeNewswire
·
September 3, 2025
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on …
Shock Top and Auntie Anne’s® Make It Official - Beer Kneads Pretzels
GlobeNewswire
·
September 3, 2025
ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), known for its bold flavors and unfiltered wheat ales, and the world’s largest hand-rolled soft pretzel franchise …
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 3, 2025
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company …
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
September 3, 2025
DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a …
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
GlobeNewswire
·
September 3, 2025
SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, …
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
GlobeNewswire
·
September 3, 2025
Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ …
Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland
GlobeNewswire
·
September 3, 2025
This marks the first export of organic certified flower for SMGH, 20th international market for Aureus branded products and 23rd market for all Avicanna products TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: …
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
GlobeNewswire
·
September 3, 2025
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever demonstration of therapeutically restored …
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
GlobeNewswire
·
September 3, 2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the …
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
GlobeNewswire
·
September 3, 2025
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD) Company Intends to Release Topline …
MicrobiotiX Finalizes KRW 20 Billion Series B, Securing Korea's First Bacteriophage Clinical Trial
GlobeNewswire
·
September 3, 2025
SEOUL, South Korea, Sept. 03, 2025 (GLOBE NEWSWIRE) -- MicrobiotiX, a biotech developing novel bacteriophage-based therapeutics, announced on the 29th that it has completed an extended Series B investment round totaling 20 billion KRW. MicrobiotiX’s …